KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Cash from Operations: 2009-2024

Historic Cash from Operations for Rigel Pharmaceuticals (RIGL) over the last 16 years, with Dec 2024 value amounting to $31.5 million.

  • Rigel Pharmaceuticals' Cash from Operations rose 10.85% to $24.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $68.2 million, marking a year-over-year increase of 535.51%. This contributed to the annual value of $31.5 million for FY2024, which is 647.99% up from last year.
  • Rigel Pharmaceuticals' Cash from Operations amounted to $31.5 million in FY2024, which was up 647.99% from -$5.7 million recorded in FY2023.
  • Rigel Pharmaceuticals' 5-year Cash from Operations high stood at $31.5 million for FY2024, and its period low was -$73.8 million during FY2022.
  • For the 3-year period, Rigel Pharmaceuticals' Cash from Operations averaged around -$16.0 million, with its median value being -$5.7 million (2023).
  • In the last 5 years, Rigel Pharmaceuticals' Cash from Operations crashed by 1,354.81% in 2022 and then surged by 647.99% in 2024.
  • Rigel Pharmaceuticals' Cash from Operations (Yearly) stood at -$52.2 million in 2020, then surged by 111.26% to $5.9 million in 2021, then plummeted by 1,354.81% to -$73.8 million in 2022, then skyrocketed by 92.21% to -$5.7 million in 2023, then surged by 647.99% to $31.5 million in 2024.